Bcl-2 expression in preinvasive and invasive cervical lesions

Purpose: To determine the correlation between bcl-2 expression and clinicopathological findings in cervical intraepithelial neoplasias (CIN I, II, III) and invasive cervical lesions, and its effect on overall survival rate.

Methods: Fifty specimens derived from 22 preinvasive and invasive cervical cancer cases up to surgical stage IIb (21 squamous cervical carcinoma and 7 adenocarcinoma cases) were preserved in paraffin blocks from primary surgery and constituted the study group. Tissues were processed and stained by immunohistochemical methods to assess the degree of bcl-2 expression.

Results: Positive bcl-2 expression was detected in 54% (13/21) of invasive lesions, while negative in 46% of cases. In CIN's, overall bcl-2 positivity was detected in 68% of cases. Bcl-2 expression was highly relevant between low grade (CIN I) and high grade (CIN II-III) lesions (p < 0.05). As regards degree of tissue staining for bcl-2 in CIN III cases, a statistically relevant difference was detected in comparison with low-grade preinvasive lesions (p < 0.05). In invasive cervical cancer cases, patients with bcl-2 positivity had a longer survival rate. By using the Cox regression model, univariate analysis did not show any specific prognostic factor to be important for survival rate, whereas, on multivariate analysis, histopathologic subtypes (p = 0.0390) and stage of tumor (p = 0.0451) had a statistically significant impact on overall survival rate.

Conclusions: Bcl-2 expression, especially in preinvasive lesions, may play a role in the apoptotic process and be regarded as a marker for disease progression. In invasive cervical carcinomas, bcl-2 expression has not been shown to be effective in overall survival rates.

Cervical intraepithelial neoplasia; Invasive cervical cancer; Bcl-2 espression

[1] Park M.: "Oncogenes: Genetic abnormalities of cell growth". In Servier C.R., Beandet A. C., Sly W. S., Valle D. (eds): The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill, Inc., 1995, 589.

[2] Harmsel B., Kuijpers J., Smedst F., Jeunink M., Trimbos B., Ramaekers F.: "Progressing imbalance between proliferation and apoptosis with increasing severity of cervical intraepithelial neoplasia". Int. J. Gynecol. Pathol., 1997, 16 (3), 205.

[3] Huang T. G., Ip S. M., Yeung W. S., Ngan N. Y.: "Changes in p21 WAFI, Prb, MdM-2, Bax and Bcl-2 expression in cervical cancer cell lines transfected with a p53 expression adenovirus". Eur. J. Cancer, 2000, 36 (2), 249.

[4] Crawford R. A. F., Caldwell C., Iles R. K., Lowe D., Shepherd J. H., Chard T.: "Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer". Br. J. Cancer, 1998, 78 (2), 210.

[5] Kurvinen K., Syrjonen K., Syrjonen S.: "p53 and bcl-2 proteins as prognostic markers in human papillomavirus-associated cervical lesions". J. Clin. Oncol., 1996, 14 (7), 2120.

[6] Dellas A., Schultheiss E., Holzgreve W., Oberholzer M., Torhost J., Gudat F.: "Investigation of the bcl-2 and c-myc expression in relationship to the ki-67 labelling index in cervical intraepithelial neoplasia". Int. J. Gynecol. Pathol., 1997, 16 (3), 212.

[7] Diakomanolis E., Dimitrakakis C., Kymionis G., Papaspyrpou I., Rodokalis A., Volugaris Z., Michalas S.: "Expression of p53 and bcl-2 in cervical carcinomas and their premalignant lesions". Proceedings of the 7" Biennial Meeting of the International Gynecologic Cancer Society, 1999, Rome, Italy, 381.

[8] Nakamura T., Nomura S., Sakai T., Nariya S.: "Expression of bcl- 2 oncoprotein in gastrointestinal and uterine carcinomas and their premalignant lesions". Human Pathol., 1997, 28 (3), 309.

[9] Saegusa M., Takano Y., Hashimura M., Shoji Y., Okayasu I.: "The possible role of bcl-2 expression in the progression of tumors of the uterine cervix". Cancer, 76 (11), 2297.

[10] Ohno T., Nakano T., Niibe Y., Tsujii H., Oka K.: "Bax protein expression correlates with radiation-induced apoptosis in radiation therapy for cervical carcinoma". Cancer, 1998, 83 (1), 103.

[11] Kokawa K., Shikone T., Otani T., Nakano T.: "Transient mcreases of apoptosis and bax expression occurring during radiotherapy in patients with invasive cervical carcinoma". Cancer, 1999, 86 (1), 79.

[12] McCluggage C., McBride H., Maxwell P., Bharucha H.: "Immunohistochemical detection of p53 and bcl-2 proteins in neoplastic and non-neoplastic endocervical glandular lesions". Int. J. Gynecol. Pathol., 1997, 16 (1), 22.

[13] Tjalma W., Weyler J., Goovaerts G., De Potter C., Van Marck E., Van Dam P.: "Prognostic value of bcl-2 expression in patients with operable carcinoma of the uterine cervix". J. Clin. Pathol., 1997, 50, 33.

[14] Tjalma W., Cuyper E., Weyler J., Van Marck E., De Potter C., Georges A., Van Dam P.: "Expression of bcl-2 in invasive and in situ carcinoma of the uterine cervix". Am. J. Obstet. Gvnecol., 1998, 178 (1), 113.

[15] Rajkumar T., Rajan S., Baruah R. K., Majhi U., Selvaluxmi G., Vasanthan A.: "Prognostic significance of bcl-2 and p53 protein expression in stage JIB and IIIB squamous cell carcinoma of the cervix". Eur. J. Gynaecol. Oncol., 1998, 19 (6), 556.

[16] Dimitrakakis C., Kymionis G., Diakomanolis E., Papaspyrou I., Rodolakis A., Arzimanoglou I. et al.:'The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions". Gynecol. Oneal., 2000, 77 (1), 129.

[17] Ter H., Van Belkum A., Quint W. et al.: "p53 and human papilloma virus type 16 in(..ervical intraepithelial neoplasia and cancer" Int. J. Gynecol. Pathol., 1995, 14, 125.

[18] Uehara T., Kuwashima M., Izomo T., Kishi K., Shiromizu K., Matsuzawa M.: "Expression of the protooncogene bcl-2 in uterine cervical squamous cell carcinoma: its relationship to clinical outcome". Eu,: J. Gynaecol. Oncol., 1995, 145, 1323.